TG Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, TG Therapeutics sits in the top decile of US sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count).
TG Therapeutics: 33 sponsored US clinical trials, 6 recruiting.
TG Therapeutics sponsors 33 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 14 completed. 6 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsing Multiple Sclerosis (RMS), with 3 trials.
Top-decile sponsor footprint
TG Therapeutics ranks in the top decile of sponsors by registered trial count (#500 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 26 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (53.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
33 total, page 1 of 1
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
NCT07673744
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
NCT06680037
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
NCT06433765
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
NCT06143514
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
NCT04130997
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
NCT04806035
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
NCT04016805
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma
NCT03828448
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)
NCT03801525
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
NCT03778073
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
NCT03379051
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
NCT03364231
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
NCT03277261
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
NCT03277248
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials
NCT03207256
An Extension of the TG1101-RMS201 Trial
NCT03381170
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis
NCT02738775
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
NCT02793583
Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy
NCT02742090
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
NCT02656303
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
NCT02612311
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
NCT02535286
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
NCT02574663
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)
NCT02301156
Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
NCT02164006
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT02100852
Ublituximab + Ibrutinib in Select B-cell Malignancies
NCT02013128
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
NCT02006485
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
NCT01767766
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
NCT01744912
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
NCT01647971
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 11 |
| Phase 3 | 6 |
Therapeutic Areas
What is open in the TG Therapeutics pipeline
6 recruiting of 33 indexed (18% open); 14 completed (42%).
Phase mix: 6 late (III/IV) vs 24 early (I/II) (early-phase heavy).
Top condition: Relapsing Multiple Sclerosis (RMS) (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
TG Therapeutics: open-pipeline peers nationwide
Peers matched on 33 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
TG Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 33 trials (± recruiting share)
- Aclaris Therapeutics · 33 trials · 3% recruiting
- Antonios Likourezos · 33 trials · 12% recruiting
- Baylor University · 33 trials · 15% recruiting
- Becton, Dickinson and Company · 33 trials · 3% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Burke Medical Research Institute · 18% recruiting · 11 trials
- Grand Valley State University · 18% recruiting · 11 trials
- Imunon · 18% recruiting · 11 trials
- InventisBio Co. · 18% recruiting · 11 trials
Related
What to do with this TG Therapeutics page
33 registered trials is a research-attention snapshot, not an endorsement of TG Therapeutics or any single study.
- 6 of TG Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Relapsing Multiple Sclerosis (RMS) is the condition TG Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsing Multiple Sclerosis (RMS) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
TG Therapeutics pipeline card: 33 registered trials from official public datasets.Report a data error.